Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Clinical Biological and Pharmacological Factors Influencing Stroke Outcome (biostroke)

This study has been completed.
Sponsor:
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by (Responsible Party):
University Hospital, Lille
ClinicalTrials.gov Identifier:
NCT00763217
First received: September 26, 2008
Last updated: May 12, 2015
Last verified: May 2015
  Purpose
In a previous suty, we have demonstrated that prior transient ischemic attack, treatment lipid-lowering drug or physical activity are associated to a better outcome of stroke. The aim of the study is to understand the mechanisms of this preventive neuroprotection by establishing link between biomarkers and preventive and neuroprotective measures.To answer to the question, we conduct a cohort study of stroke patients.

Condition
Stroke

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterization of Clinical, Biological and Pharmacological Markers of Stroke Outcome

Further study details as provided by University Hospital, Lille:

Primary Outcome Measures:
  • severity of stroke measured by NIH severity score [ Time Frame: inclusion, day7, month3, year3 ]

Secondary Outcome Measures:
  • clinical, pharmacological and biological (metabolic, inflammation, hemostasis...) cognitive status [ Time Frame: inclusion and year3 ]

Biospecimen Retention:   Samples Without DNA
whole blood and serum

Enrollment: 550
Study Start Date: June 2005
Study Completion Date: June 2012
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
stroke patient cohort
Patients with an hemispheric ischemic or hemorrhage stroke hospitalized during the 48h following the beginning of stroke

Detailed Description:

In the cohort, the severity of stroke (NIHSS) will be correlated with :

  • clinical factors,
  • pharmacological factors,
  • biological factors (inflammatory markers, hemostasis...)
  Eligibility

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Cohort of stroke patient
Criteria

Inclusion Criteria:

  • ischemic or hemorrhage stroke
  • hemispheric stroke
  • stroke dating from less 48h

Exclusion Criteria:

  • non hemispheric stroke
  • malformative intracranial hemorrhage
  • traumatic intracranial hemorrhage
  • subarachnoidal hemorrhage
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00763217

Locations
France
Lille University Hospital - Service de Neurologie vasculaire
Lille, France
Sponsors and Collaborators
University Hospital, Lille
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Principal Investigator: regis BORDET, MD,PhD Lille University Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: University Hospital, Lille
ClinicalTrials.gov Identifier: NCT00763217     History of Changes
Other Study ID Numbers: CP 05/15
PHRC 2004/1901 ( Other Identifier: DHOS )
Study First Received: September 26, 2008
Last Updated: May 12, 2015

Keywords provided by University Hospital, Lille:
inflammation
coagulation
neuroprotection
drugs
clinical neurology
pharmacology
biological factors

Additional relevant MeSH terms:
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 22, 2017